Gilva Therapeutics, INC.

GV-100 is a first-in-class, non-hydroxamate HDAC6 inhibitor for ADPKD. It modulates pathways associated with PC1 and
improves mitochondrial function, reducing inflammation and fibrosis. Demonstrates strong preclinical efficacy vs comparators, favorable PK/safety, and is advancing to Phase 1.

• Clinical Trial Collaboration
• Co-Development
• Out-Licensing
• Strategic Alliance
• Collaborative R&D